| Anson Resources Limited (ASN) ORDINARY FULLY PAID |
Materials |
$100 |
Quarterly Activities and Cashflow Report
|
30 Apr 2025 8:49AM |
$0.056 |
$0.062 |
risen by
10.71%
|
|
ASN - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of the Definitive Feasibility Study (DFS) for the Paradox Lithium Project, confirming robust project economics.
- Advancement in permitting, with key approvals secured for the Paradox Project.
- Resource expansion drilling conducted at the Paradox Project, extending the known lithium resource.
- Continued engagement with potential offtake partners and strategic parties regarding project development.
- Update on the Green River Lithium Project and the Yellow Cat Uranium-Vanadium Project in Utah.
- Progress at the Ajana and Hooley Well base metal projects in Western Australia.
- Successful capital raising activities to fund ongoing exploration and development.
- Quarterly cash outflows primarily related to exploration and evaluation, with closing cash balance provided.
- Ongoing commitment to environmental, social, and corporate governance (ESG) initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mach7 Technologies Limited (M7T) ORDINARY FULLY PAID |
Health Care |
$127 |
Update - Notification of buy-back - M7T
|
30 Apr 2025 8:49AM |
$0.320 |
$0.540 |
risen by
68.75%
|
|
| Acrow Limited (ACF) ORDINARY FULLY PAID |
Industrials |
$325 |
ACF Completes Two Industrial Access Deals, Updates Guidance
|
30 Apr 2025 8:48AM |
$1.035 |
$1.045 |
risen by
0.97%
|
|
ACF - Price-sensitive ASX Announcement
Full Release
Key Points
- Acrow Limited completed two strategic industrial access acquisitions: Uni-span Australia Pty Ltd and Uni-span Formwork Hire Pty Ltd.
- The acquisitions strengthen Acrow's market presence in Western Australia and the industrial sector.
- Acrow updated its FY24 underlying EBITDA guidance to $47-48 million, up from previous forecasts.
- The acquisitions are expected to deliver operational synergies and expand customer offerings.
- Integration plans are in progress, with a focus on leveraging shared expertise and resources.
- The deals align with Acrow’s growth strategy to expand its footprint in key regions and sectors.
- Acrow remains committed to delivering shareholder value and operational excellence post-acquisition.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Titomic Limited (TTT) ORDINARY FULLY PAID |
Materials |
$354 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Apr 2025 8:48AM |
$0.240 |
$0.225 |
fallen by
6.25%
|
|
TTT - Price-sensitive ASX Announcement
Full Release
Key Points
- Titomic Limited reported its activities and cash flow for the quarter ended 30 June 2023.
- The company is focused on commercializing its Titomic Kinetic Fusion technology.
- Key partnerships and agreements were established with international organizations to expand market reach.
- Titomic achieved successful equipment deliveries and commissioning during the quarter.
- Receipts from customers and R&D incentives contributed to cash inflows.
- Operational cost management and a focus on core business activities highlighted.
- The company maintains a stable cash position.
- Outlook emphasizes ongoing cost reduction, revenue growth, and technology commercialization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Chimeric Therapeutics Limited (CHM) ORDINARY FULLY PAID |
Health Care |
$13 |
Application for quotation of securities - CHM
|
30 Apr 2025 8:48AM |
$0.005 |
$0.004 |
fallen by
30%
|
|
| Tambourah Metals Ltd (TMB) ORDINARY FULLY PAID |
Materials |
$11 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Apr 2025 8:48AM |
$0.027 |
$0.044 |
risen by
62.96%
|
|
TMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Ongoing exploration at Tambourah Gold and Lithium Project, Russian Jack, and Julimar North.
- Secured and progressed heritage agreements and tenement applications.
- Conducted reconnaissance drilling and geochemical sampling programs.
- Closing cash balance of $2.4M at the end of the quarter.
- No substantive mining production or development cash outflows during the quarter.
- Continued focus on project generation and portfolio advancement.
- Compliance with ASX Listing Rule 5.3 and 5.4.
- No mining or production activities were conducted.
- Strategic commitment to prudent cash management and exploration growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Birddog Technology Limited (BDT) ORDINARY FULLY PAID |
Information Technology |
- |
BDT March 2025 Quarterly Activities Report & Appendix 4C
|
30 Apr 2025 8:48AM |
$0.047 |
$0.060 |
risen by
27.66%
|
|
BDT - Price-sensitive ASX Announcement
Full Release
Key Points
- The report covers Birddog Technology Limited's operational and financial activities for the quarter ending March 2025.
- BDT has focused on expanding its product distribution network globally, with a particular emphasis on growth in the United States and Europe.
- The company pursued strategic partnerships and collaborations to increase its market share in the broadcast and AV (audio-visual) sectors.
- BDT continued to invest in research and development, enhancing its product offerings including camera and video transmission technology.
- The report details the company’s cash flow for the quarter, including receipts from customers, payments for operating activities, and the end-of-quarter cash balance.
- BDT received government grants and incentives, which supported ongoing product development and operational initiatives.
- The company maintained its commitment to innovation, launching new products and software updates to meet evolving industry standards.
- Management reported a strong pipeline for upcoming customer orders and potential new contracts.
- Risks and challenges identified include ongoing supply chain constraints, foreign exchange fluctuations, and competitive pressures.
- The company reports compliance with ASX Listing Rule 4.7C, confirming that related party payments were made as outlined, primarily for director fees and salaries.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| White Cliff Minerals Limited (WCN) ORDINARY FULLY PAID |
Materials |
$48 |
First Assay Results From Rae Delivers 58m @ 3.08% Copper
|
30 Apr 2025 8:48AM |
$0.019 |
$0.019 |
fallen by
0%
|
|
WCN - Price-sensitive ASX Announcement
Full Release
Key Points
- First assay results from the Rae Project deliver 58m at 3.08% copper from the initial diamond drill hole.
- Results confirm the presence of broad, high-grade copper mineralisation at the Rae Prospect.
- The intercept supports White Cliff’s exploration model and highlights the project’s potential.
- Ongoing and additional drilling campaigns are planned to further test the mineralisation at Rae and nearby prospects.
- The project is located in Nunavut, Canada, within a region known for prospective copper mineralisation.
- The company provides details on the drilling methodology, sample handling, and assay techniques.
- Geological observations indicate mineralisation associated with sheared and altered mafic rocks.
- The results represent a significant milestone for White Cliff Minerals’ exploration efforts in the region.
- Further updates and assay results from subsequent holes are anticipated.
- The project forms part of White Cliff’s broader strategy to develop high-grade copper resources.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| RPMGlobal Holdings Limited (RUL) ORDINARY FULLY PAID |
Information Technology |
$1,091 |
Notification of cessation of securities - RUL
|
30 Apr 2025 8:48AM |
$2.810 |
$4.925 |
risen by
75.27%
|
|
| Dalaroo Metals Ltd (DAL) ORDINARY FULLY PAID |
Materials |
$14 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Apr 2025 8:47AM |
$0.026 |
$0.045 |
risen by
73.08%
|
|
DAL - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report covers period ending 31 March 2024.
- Ongoing exploration at Lyons River and Namban Projects in Western Australia.
- Focus on lithium-pegmatite and base metal targets.
- Field reconnaissance, rock chip and soil sampling completed.
- Results from sampling programs are pending.
- No mining production or sales reported this quarter.
- Company maintains strong cash position to fund activities.
- Outline of related party transactions and payments.
- Business risks and future work plans discussed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Urbanise.Com Limited (UBN) ORDINARY FULLY PAID |
Information Technology |
$58 |
Appendix 4C and Quarterly Activities Report
|
30 Apr 2025 8:47AM |
$0.805 |
$0.730 |
fallen by
9.32%
|
|
UBN - Price-sensitive ASX Announcement
Full Release
Key Points
- Urbanise.Com Limited reported for the quarter ending 31 March 2024.
- The company continues to invest in product development for its cloud-based platforms.
- Annual recurring revenue (ARR) growth remains a focus.
- Urbanise is optimizing costs to improve financial performance.
- Updates provided on cash receipts, payments, and cash balance at quarter end.
- Customer acquisition, contract renewals, and product enhancements progressed during the quarter.
- Business development and sales pipeline initiatives are ongoing.
- Disclosure of related party transactions and expenditure breakdowns.
- The company maintains a positive outlook with continued focus on growth and operational efficiency.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Burgundy Diamond Mines Limited (BDM) ORDINARY FULLY PAID |
Materials |
$24 |
Quarterly activities report
|
30 Apr 2025 8:47AM |
$0.038 |
$0.017 |
fallen by
55.26%
|
|
BDM - Price-sensitive ASX Announcement
Full Release
Key Points
- Ekati Diamond Mine ramp-up continues with increased production volumes and operational improvements.
- Positive diamond sales results with improved pricing and demand for certain categories.
- Focus on cost optimization and operational efficiencies at the Ekati site.
- Active exploration programs underway, including drilling at new kimberlite targets.
- Strong health and safety performance with zero lost time injuries reported for the quarter.
- Solid financial position maintained, with cash reserves and ongoing cost management.
- Progress made in sustainability and environmental stewardship initiatives.
- Strategic investments and partnerships explored to enhance growth prospects.
- Board and management changes implemented to strengthen leadership capabilities.
- Outlook remains positive with a focus on maximizing value from existing assets and advancing exploration pipeline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$101 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Apr 2025 8:47AM |
$0.025 |
$0.320 |
risen by
1,180%
|
|
IMU - Price-sensitive ASX Announcement
Full Release
Key Points
- Imugene progressed clinical and pre-clinical programs, including HER-Vaxx, PD1-Vaxx, and onCARlytics.
- Key clinical trial milestones achieved during the quarter, such as patient recruitment and dosing.
- Obtained regulatory approvals to expand clinical trials into the US and South Korea.
- No revenue from product sales as the company remains in the pre-revenue stage.
- Cash balance at the end of the quarter was approximately $143.5 million.
- Research and development remained the largest expenditure category.
- Payments to related parties were primarily directors’ fees and consulting expenses.
- Imugene is well-funded to support ongoing and future clinical trials.
- No financing or investing flows reported during the quarter.
- Appendix 4C details the cash inflows and outflows for the three-month period ending 31 March 2023.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fluence Corporation Limited (FLC) ORDINARY FULLY PAID |
Utilities |
$111 |
Fluence Q1 2025 Business Update
|
30 Apr 2025 8:47AM |
$0.047 |
$0.097 |
risen by
106.38%
|
|
FLC - Price-sensitive ASX Announcement
Full Release
Key Points
- Fluence's MABR technology continues to see growing adoption, particularly in Asia.
- First quarter of 2025 demonstrated solid order inflows and project executions.
- Water-as-a-Service business model expanded, with notable contracts in Mexico and the USA.
- Gross profit margin improved due to higher quality sales and operational efficiencies.
- Ongoing reduction in operating expenses through disciplined cost management.
- Strong pipeline of new project opportunities globally, with emphasis on recurring revenue streams.
- Maintained a robust cash position to fund growth initiatives.
- Strategic focus remains on technology leadership, sustainable water solutions, and expanding WaaS footprint.
- Positive outlook for FY2025 with confidence in meeting financial and operational targets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fluence Corporation Limited (FLC) ORDINARY FULLY PAID |
Utilities |
$111 |
Fluence Q1 2025 Update Investor Presentation
|
30 Apr 2025 8:47AM |
$0.047 |
$0.097 |
risen by
106.38%
|
|
FLC - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong Q1 2025 performance with revenue growth and positive EBITDA targeted for the full year.
- Continued expansion and sales of Smart Product Solutions, especially MABR-based solutions.
- Significant contribution from recurring revenue contracts and service agreements.
- Active pursuit and execution of new projects in key geographic markets including China, Southeast Asia, and the Americas.
- Strategic partnerships and new agreements enhancing market position in water and wastewater treatment.
- Focus on technology leadership and implementation of decentralized treatment solutions.
- Ongoing delivery of major projects and strengthening of project pipeline.
- Confidence in achieving FY25 guidance and further operational improvements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AF Legal Group Ltd (AFL) ORDINARY FULLY PAID |
Industrials |
$17 |
Q3 FY25 - Quarterly Update
|
30 Apr 2025 8:47AM |
$0.110 |
$0.180 |
risen by
63.64%
|
|
AFL - Price-sensitive ASX Announcement
Full Release
Key Points
- AF Legal Group Ltd (AFL) reports continued revenue and client growth in Q3 FY25.
- Ongoing investment in technology and staff development supports operational improvements.
- The firm is expanding its range of legal service offerings to better meet client needs.
- Key strategic initiatives center on market share growth, operational efficiency, and client service excellence.
- Management remains focused on long-term sustainable growth.
- Recent initiatives have positively impacted the company’s competitive position.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Zip Co Limited (ZIP) ORDINARY FULLY PAID |
Financials |
$3,879 |
Update - Notification of buy-back - ZIP
|
30 Apr 2025 8:47AM |
$1.730 |
$3.040 |
risen by
75.72%
|
|
| Chimeric Therapeutics Limited (CHM) ORDINARY FULLY PAID |
Health Care |
$13 |
Application for quotation of securities - CHM
|
30 Apr 2025 8:47AM |
$0.005 |
$0.004 |
fallen by
30%
|
|
| Cosmo Metals Limited (CMO) ORDINARY FULLY PAID |
Materials |
$7 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Apr 2025 8:47AM |
$0.018 |
$0.017 |
fallen by
5.56%
|
|
CMO - Price-sensitive ASX Announcement
Full Release
Key Points
- Drilling programs completed at Mt Venn and Eastern Mafic prospects within the Yamarna Project, Western Australia.
- Follow-up drilling confirmed zones of nickel, copper, and cobalt mineralisation.
- Exploration for rare earth elements (REE) commenced with a review and sampling at priority targets.
- Significant drill results reported, identifying further targets for future exploration.
- The company maintains a strong focus on systematic exploration to expand its understanding of mineralisation.
- Summary of quarterly cash flows provided, showing major expenditure on exploration and administration.
- Cosmo Metals Limited held $1.1 million in cash at the end of the quarter.
- Appointment of a new chief executive officer announced during the quarter.
- Ongoing engagement with investors and updates on project milestones.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Naos Emerging Opportunities Company Limited (NCC) ORDINARY FULLY PAID |
Financials |
$30 |
Change of Director's Interest Notice - S Williams
|
30 Apr 2025 8:47AM |
$0.295 |
$0.405 |
risen by
37.29%
|
|
| Plenti Group Limited (PLT) ORDINARY FULLY PAID |
Financials |
$196 |
4Q25 update - Record originations and Cash NPAT
|
30 Apr 2025 8:47AM |
$0.820 |
$1.085 |
risen by
32.32%
|
|
PLT - Price-sensitive ASX Announcement
Full Release
Key Points
- Record loan originations achieved in 4Q25.
- Positive cash NPAT delivered for the period.
- Loan book growth driven by personal, automotive, and renewable energy finance segments.
- Strong credit performance maintained across portfolio.
- Improved funding efficiency and cost management reported.
- Increased brand awareness and enhanced customer experience through technology.
- Expanded distribution partnerships and industry collaborations.
- Ongoing profitability and positive outlook for future growth reaffirmed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arafura Rare Earths Ltd (ARU) ORDINARY FULLY PAID |
Materials |
$676 |
Quarterly Activities Report and Appendix 5B
|
30 Apr 2025 8:47AM |
$0.200 |
$0.230 |
risen by
15%
|
|
ARU - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities Report covers the period ending 31 March 2024.
- Significant construction progress at the Nolans Project, with key early works completed.
- Ongoing procurement and contract awards for major project components.
- Advancements in project financing and funding, including engagement with lenders and government agencies.
- Updates on offtake agreements with international customers.
- Focus on safety, environmental compliance, and community engagement.
- Financial summary provided, including cash position and operational expenditure.
- Company remains on track with project schedule and budget.
- Regulatory approvals and permitting processes are progressing as planned.
- Appendix 5B included with detailed cash flow statement and financial disclosures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| VHM Limited (VHM) ORDINARY FULLY PAID |
Materials |
$97 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Apr 2025 8:47AM |
$0.310 |
$0.335 |
risen by
8.06%
|
|
VHM - Price-sensitive ASX Announcement
Full Release
Key Points
- VHM Limited continued mineral exploration activities at its North Stanmore Rare Earth Element (REE) project in Western Australia during the March 2023 quarter.
- The company reported positive results from auger drilling at the North Stanmore project, indicating significant REE mineralisation, particularly heavy rare earths.
- A maiden Mineral Resource Estimate for North Stanmore was announced, comprising 60Mt at 1,153ppm TREO, with substantial proportions of valuable heavy REEs such as dysprosium and terbium.
- VHM Limited advanced metallurgical test work, confirming successful recovery of REEs using acid leach extraction, with further optimization ongoing.
- Corporate activities included appointment of Ms. Jane Allen as Chief Financial Officer, and the company remains focused on progressing the North Stanmore project towards development.
- Cash outflows during the quarter primarily related to exploration and evaluation activities, with a closing cash balance of $2.9 million as of 31 March 2023.
- The company estimates that its available funding is sufficient for the next quarter's planned activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fluence Corporation Limited (FLC) ORDINARY FULLY PAID |
Utilities |
$111 |
Appendix 4C - Quarterly
|
30 Apr 2025 8:47AM |
$0.047 |
$0.097 |
risen by
106.38%
|
|
FLC - Price-sensitive ASX Announcement
Full Release
Key Points
- FLC published its Appendix 4C Quarterly Cash Flow Report for the quarter ending 31 March 2023.
- Cash receipts from customers totaled US$23.6 million in Q1 2023.
- Net cash used in operating activities was US$2.1 million for the quarter.
- The company secured significant new contract wins, including water and wastewater treatment solutions.
- FLC continues to expand its recurring revenue base through Build-Own-Operate (BOO) and recurring contracts.
- Strong sales pipeline with ongoing bids and project negotiations in various international markets.
- Cost management initiatives remain in focus to support the path to profitability.
- Available cash at the end of the quarter was US$19.0 million.
- No payments were made to related parties or their associates during the reporting period.
- The company is focused on accelerating the shift towards higher-margin, recurring revenue business.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PainChek Ltd (PCK) ORDINARY FULLY PAID |
Health Care |
$62 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Apr 2025 8:47AM |
$0.039 |
$0.295 |
risen by
666.23%
|
|
PCK - Price-sensitive ASX Announcement
Full Release
Key Points
- PainChek achieved a record increase in contracted beds, now totaling 158,999 globally, representing a 68% year-on-year growth.
- Annual recurring revenue reached $4.3 million, up 53% from the previous year.
- Estia Health signed a national agreement to implement PainChek across 73 residential aged care homes, significantly boosting user numbers.
- Everglow Community Care Links contracted PainChek to support 1,000 home care clients, marking further penetration into the home care sector.
- PainChek conducted a record 145,830 clinical assessments in the quarter, a 33% year-on-year increase.
- User activity also hit a new high with 5,942 unique users during the quarter.
- The UK market continues to show strong momentum, with more than 11,000 contracted beds and new contracts signed with multiple care providers.
- The company advanced its product development and regulatory submission for dementia and intellectual disability applications.
- PainChek’s cash balance was $8.3 million at 31 March 2024, with net cash outflows of $1.2 million for the quarter.
- Cash reserves are sufficient to fund operations for more than five quarters, based on current cash burn.
- The company signed additional commercial and research partnerships, supporting market expansion and validating clinical utility.
- Ongoing investments in product development and commercialisation remain a key focus for PainChek.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
